Common Contracts

Entered into Subscription Agreement, Exclusive Licensing and Commercial Partnership Agreement with Telix; Entered into Memorandum of Strategic Cooperation with Jiangsu Institute of Nuclear Medicine; and

November 1st, 2020

• Filed
  November 1st, 2020

The Board is pleased to announce that the Group has entered into the following transactions in the field of radionuclide-drug conjugates (RDC), focusing on highly innovative and high- barrier radiological diagnostic and therapeutic drugs.